JP2015172090A5 - - Google Patents

Download PDF

Info

Publication number
JP2015172090A5
JP2015172090A5 JP2015135830A JP2015135830A JP2015172090A5 JP 2015172090 A5 JP2015172090 A5 JP 2015172090A5 JP 2015135830 A JP2015135830 A JP 2015135830A JP 2015135830 A JP2015135830 A JP 2015135830A JP 2015172090 A5 JP2015172090 A5 JP 2015172090A5
Authority
JP
Japan
Prior art keywords
composition
antibody
antigen
transplant
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015135830A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015172090A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2015172090A publication Critical patent/JP2015172090A/ja
Publication of JP2015172090A5 publication Critical patent/JP2015172090A5/ja
Pending legal-status Critical Current

Links

JP2015135830A 2007-07-25 2015-07-07 Cd200に対する抗体および免疫応答への使用 Pending JP2015172090A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96202207P 2007-07-25 2007-07-25
US60/962,022 2007-07-25

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2013110577A Division JP5926702B2 (ja) 2007-07-25 2013-05-27 Cd200に対する抗体および免疫応答への使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016052050A Division JP2016117762A (ja) 2007-07-25 2016-03-16 Cd200に対する抗体および免疫応答への使用

Publications (2)

Publication Number Publication Date
JP2015172090A JP2015172090A (ja) 2015-10-01
JP2015172090A5 true JP2015172090A5 (https=) 2016-05-12

Family

ID=40001380

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2010518230A Pending JP2010534243A (ja) 2007-07-25 2008-07-25 Cd200に対する抗体および免疫応答への使用
JP2013110577A Expired - Fee Related JP5926702B2 (ja) 2007-07-25 2013-05-27 Cd200に対する抗体および免疫応答への使用
JP2015135830A Pending JP2015172090A (ja) 2007-07-25 2015-07-07 Cd200に対する抗体および免疫応答への使用
JP2016052050A Pending JP2016117762A (ja) 2007-07-25 2016-03-16 Cd200に対する抗体および免疫応答への使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010518230A Pending JP2010534243A (ja) 2007-07-25 2008-07-25 Cd200に対する抗体および免疫応答への使用
JP2013110577A Expired - Fee Related JP5926702B2 (ja) 2007-07-25 2013-05-27 Cd200に対する抗体および免疫応答への使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016052050A Pending JP2016117762A (ja) 2007-07-25 2016-03-16 Cd200に対する抗体および免疫応答への使用

Country Status (9)

Country Link
US (3) US8252285B2 (https=)
EP (1) EP2178561A1 (https=)
JP (4) JP2010534243A (https=)
KR (1) KR20100041849A (https=)
AU (1) AU2008279619B2 (https=)
BR (1) BRPI0814644A2 (https=)
CA (1) CA2697159C (https=)
MX (1) MX2010000981A (https=)
WO (1) WO2009014745A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252285B2 (en) 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses
WO2011100538A1 (en) 2010-02-11 2011-08-18 Alexion Pharmaceuticals, Inc. Therapeutic methods using an ti-cd200 antibodies
AU2012212066A1 (en) * 2011-02-03 2013-08-15 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
US9309305B2 (en) 2011-06-10 2016-04-12 National Research Council Of Canada Anti-ricin antibodies and uses thereof
EP2723380B1 (en) 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
CA2969384A1 (en) * 2014-12-17 2016-06-23 Cellectis Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
US10888609B2 (en) 2015-11-03 2021-01-12 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
KR101968246B1 (ko) * 2017-04-27 2019-04-11 서울대학교산학협력단 이종 각막 이식에서 항 cd20 단일클론항체 및 타클로리무스의 복합면역억제 방법
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US11802154B2 (en) 2017-12-20 2023-10-31 Alexion Pharmaceuticals, Inc. Humanized anti-CD200 antibodies and uses thereof
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
US12414983B2 (en) 2019-01-14 2025-09-16 Regents Of The University Of Minnesota CD200AR ligands for cancer immunotherapy
EP4296280A1 (en) 2022-06-21 2023-12-27 F. Hoffmann-La Roche AG Cd123 and cd200 as markers for the diagnosis and immune-eradication of leukemic stem cells (lscs)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223729B2 (en) * 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
EP1032662B1 (en) * 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US20060057651A1 (en) * 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
MXPA05006978A (es) 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
HUE028179T2 (en) * 2006-01-12 2016-12-28 Alexion Pharma Inc Antibodies to OX-2 / CD200 and their use
WO2009014744A1 (en) 2007-07-25 2009-01-29 Alexion Pharmaceutical, Inc. Methods and compositions for treating autoimmune disease
US8252285B2 (en) * 2007-07-25 2012-08-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof in inhibiting immune responses

Similar Documents

Publication Publication Date Title
JP2015172090A5 (https=)
JP2010534243A5 (https=)
JP2022501428A5 (https=)
JP6242808B2 (ja) 所望の特異性を有するモノクローナル自己抗体を提供する方法
JP5926702B2 (ja) Cd200に対する抗体および免疫応答への使用
Zaza et al. Monoclonal antibody therapy and renal transplantation: focus on adverse effects
WO2008137915A3 (en) Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
AU2014220777B2 (en) Anti-CD26 antibodies and uses thereof
Mayer et al. Emerging drugs for antibody-mediated rejection after kidney transplantation: a focus on phase II & III trials
RU2015145543A (ru) Способы и композиции для лечения болезни дего
ES2341341T3 (es) Anticuerpos terapeuticos humanizados contra las isoformas cd45.
RU2017118985A (ru) Антитела, их применение и способы применения
Padiyar et al. Induction antibody therapy in kidney transplantation
US12173081B2 (en) CD19/CD38 multispecific antibodies
JP7825834B2 (ja) 抗c4dキメラ抗原受容体調節性t細胞およびその使用
JP2019508448A (ja) 移植片対宿主病予防の方法
JP2024028850A (ja) 抗pd-l1抗体及びその製薬用途
Broeders et al. Mycophenolate mofetil, together with cyclosporin A, prevents anti-OKT3 antibody response in kidney transplant recipients.
JP2025066696A (ja) 移植片対宿主病(GvHD)の防止又は処置のための抗CCR7 MABの使用
JP6881658B2 (ja) Pd−1/cd3二重特異性タンパク質による血液がん治療
Sulemanjee et al. The first year post–heart transplantation: Use of immunosuppressive drugs and early complications
US20210395343A1 (en) Ivig composition and method of treatment of antibody deficient patients
Atanasov et al. Induction and Maintenance Immunosuppression in Intestinal Transplantation
EA051410B1 (ru) Конъюгат антитело-лекарственное средство и его применение
Webster The addition of anti-CD25 antibody induction to standard immunosuppressive therapy for kidney transplant recipients